06.08.21

Ocuphire Announces Appointment of Jay S. Pepose, MD, PhD, to Its Board of Directors

Source: Ocuphire

Ocuphire Pharma announced the appointment of Jay S. Pepose, MD, PhD, to its Board of Directors. Concurrent to Dr. Pepose’s appointment at Ocuphire’s annual shareholder meeting on June 7, Alan Meyer, MBA, retired from his role on the Board of Directors, having served since April 2018.

“We are very pleased to welcome Dr. Pepose to our Board of Directors,” Cam Gallagher, Chair of Ocuphire’s Board of Directors, said in a company news release. “As a member of our Medical Advisory Board, Dr. Pepose has already made significant contributions to our clinical programs by advising us on a wide range of issues, including drug development and regulatory strategy and mid to late-stage clinical trial design. Dr. Pepose’s appointment as a director also comes at an opportune time for our company, as we expect to generate further data readouts for Nyxol and APX3330 in 2021 and 2022. The Board believes Jay’s expertise in ophthalmologic medicine coupled with his understanding of patient-physician market dynamics will provide us with an extraordinarily well-balanced view on both the medical and commercial potential of our drug candidates.”

Dr. Jay Pepose is a recognized thought leader in the field of ophthalmology, with nearly 40 years of experience as both a treating physician and a widely published researcher. He is the founder and the current Medical Director of the Pepose Vision Institute, and also founded the Midwest Corneal Research Foundation, now the Midwest Vision Research Foundation, as an independent spinout of the Pepose Vision Institute. He is a professor of clinical ophthalmology and visual sciences at Washington University School of Medicine in St. Louis, where he is a specialist in refractive surgery and corneal and external diseases. Dr. Pepose is also a consultant to the Centers for Disease Control and Prevention.

Dr. Pepose is actively involved in clinical research trials and has been the recipient of R-01 grant support from the National Eye Institute. He has served on the editorial boards of several prestigious journals, including the American Journal of Ophthalmology, Investigative Ophthalmology & Visual Science (IOVS), Cornea, and The Journal of Refractive Surgery. He has published over 210 peer-reviewed articles and a book on ocular infections and inflammatory diseases. Since 1990, Dr. Pepose has also served as an investigator on over 30 separate clinical trials, evaluating new therapeutics and technology across a broad range of ophthalmic indications, including adenoviral and bacterial conjunctivitis, meibomian gland dysfunction, dry eye disease, open-angle glaucoma, ocular hypertension, anterior uveitis, and reversal of presbyopia.

 

Related Content